Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax delivered a clean beat on paper. The third-quarter loss of $0.19 per share was well ahead of the -$0.37 consensus, a 48.6% surprise. Revenue of $68.3 million topped the $50.61 million estimate by 34.9%. Earnings improved 69.4% year over year as the net loss shrank to $31 million from $202 million, while revenue slipped 3.0%. The bigger news came after quarter-end. Sanofi started its Phase 3 influenza-COVID combination trial in Europe in October, earning Novavax a $125 million milestone. That drove a $145 million increase in the full-year adjusted revenue framework, to a $400 million midpoint. The central tension is that the guidance raise is mostly a partner event. Beneath it, the recurring revenue base is shrinking, and the timeline to profitability just moved further out.

The quality of the quarter deserves scrutiny. Much of the year-over-year improvement in the loss comes from lapping one-time hits. The year-ago quarter carried a $97 million impairment on assets held for sale and a $28.7 million loss on debt extinguishment. GAAP R&D fell 47%, which looks dramatic, but non-GAAP R&D declined only 7%, to $48.7 million. The gap reflects R&D reimbursement from Sanofi dropping from $45.8 million to $3.8 million. That $42 million reimbursement decline is also what pulled licensing and royalty revenue down 25%. In other words, a large portion of the expense reduction simply mirrors revenue that has disappeared. The revenue beat also leaned on $11 million of non-cash deferred royalty recognition tied to SK bioscience's prior sales in South Korea. Sanofi-related revenue fell 61%. The genuine bright spot was product sales, which rose 91% to $26 million on Nuvaxovid supply to Sanofi and Matrix-M shipments to partners.

The conference call offered a more constructive operating picture than the income statement:

• **Nuvaxovid demand:** Season-to-date U.S. shots already equal the entire prior season, and recent weekly U.S. market volumes are running above 110% of last year. That compares with a flattish market expectation earlier in the year.
• **Raised framework components:** Excluding the milestone, the guidance increase was a modest $20 million, made up of $5 million in Nuvaxovid sales, $5 million in adjuvant supply and $10 million in royalties.
• **Expense guidance:** GAAP R&D plus SG&A guidance improved by $5 million at the midpoint, to $385 million.
• **Cash runway:** Management extended its runway to well into 2029, from into 2028.
• **Restructuring:** The company plans to cut its operating footprint by more than half and reduce headcount to under half of first-quarter 2026 levels by 2028.

The forward calendar is now more concrete, but it is also longer. Sanofi confirmed plans for a U.S. Phase 3 combination trial in 2027. A U.S. launch, which would trigger a $225 million milestone plus high-single-digit to sub-teens royalties, is targeted for 2029. The $75 million technology-transfer milestone is now expected around mid-2027. As a result, management is realigning its non-GAAP profitability target with the 2029 launch, after previously framing it as early as 2028.

Bears have legitimate ammunition on several fronts:

• R&D reimbursement and Sanofi upfront amortization will dwindle and end during 2027.
• Nuvaxovid advance-purchase sales will be excluded from the 2027 framework.
• Management flagged that 2026 Matrix-M demand of roughly $55 million runs up to $15 million above the expected future run rate because of order timing.
• Up to $35 million in non-cash write-offs is expected in 2027 from facility consolidation.
• Cash and receivables fell to $676 million from $818 million in the first quarter.
• No new licensing deal has been announced since Pfizer in January.

The C. difficile program, targeting the clinic as early as 2027, and early Matrix-M oncology work are optionality rather than near-term value.

The market setup is more complicated than the surprise implies. Shares closed at $10.65 the day before the report, up 36.1% from the $7.82 open after the August release and 14.3% above the 200-day moving average of $9.32. However, the stock had already pulled back 20.4% from its 52-week high of $13.39, set on October 5. Investors appear to have priced in at least part of the Sanofi trial start before it was formally reported. Investor sentiment sat near neutral but drifted modestly lower, from -0.019 to -0.088. That is a small shift, but it suggests enthusiasm did not build into the print. The Earnings Whispers trend signals lean negative: sequential growth and AVWAP readings are weak, even as the price trend remains positive.

The bottom line is that Novavax beat estimates and raised guidance, but the improvement rests largely on a partner milestone, lapped charges and non-cash revenue. The legacy Sanofi transition income that has propped up the top line is fading toward zero, and the profitability goal now depends on a U.S. combination-vaccine launch roughly three years away. Strong Nuvaxovid season trends, a runway into 2029 and deeper cost cuts make the story more durable. For now, though, this remains a milestone-dependent company whose stock has already given back a meaningful part of its October run.

Read our earnings preview for Novavax, Inc.: https://www.earningswhispers.com/article/NVAX/22450

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.